Fusobacterium nucleatum: A Rare Presentation of Hepatic Abscesses

Fusobacterium nucleatum is a facultative anaerobic gram-negative bacillus found in the oral cavity, gastrointestinal tract, and genitourinary tract. Fusobacterium nucleatum is a rare cause of hepatic abscesses and empyema. We describe a case of Fusobacterium liver abscess and empyema, resulting in extensive thrombophlebitis in intraabdominal and extremity veins. A 78-year-old female with past medical history significant for bicytopenia and tooth repair 8 months prior presented with mild diarrhea and fatigue. She was febrile, tachycardic, and tachypneic. On physical exam, she had mild epigastric tenderness and bilateral lower extremity pitting edema. Labs were notable for an AKI and elevated LFTs. Imaging revealed multiple \u3e10cm hepatic abscesses, a small right pleural effusion, a segmental pulmonary embolism, along with extensive intraabdominal and extremity DVTs. Vascular surgery did not recommend intervention. She underwent IR drainage of three abscesses as well as chest tube drainage of pleural effusion. Blood, abscesses, and pleural effusion culture grew Fusobacterium nucleatum. Plural effusion also grew Lactobacillus rhamnosus. She received metronidazole and was eventually switched to ampicillin/sulbactam. Source and malignancy work up were negative. The source of Fusobacterium nucleatum hepatic abscesses in descending order of frequency is periodontal flora, cryptogenic, and gastrointestinal tract. Given her diarrhea, the source may have been translocation from her gastrointestinal tract, however, it could also be periodontal due to her recent tooth repair. Treatment includes source control and antibiotics, ranging from 2 weeks to 6 months. This case illustrates the rare disease process of Fusobacterium hepatic abscess formation and the bacteria’s thrombogenic characteristics.https://scholarlycommons.henryford.com/merf2020caserpt/1044/thumbnail.jp

An Unusual Case of Urban Actinomyces Pyogenes Infective Endocarditis

Actinomyces pyogenes is a gram positive bacillus known to cause pyogenic infections in animals with rare reports in humans with farm animal exposure. A 52-year-old male who was an active injection drug user presented to the emergency department with right-sided weakness, expressive aphasia, and altered mental status. He was found to be tachycardic and febrile. The patient was admitted two weeks prior for bilateral pneumonia and blood cultures grew Actinomyces pyogenes. Infectious Diseases was not consulted during that admission. On this admission, CT head showed a large left MCA ischemic stroke. Further imaging was concerning for septic emboli to the lungs and kidney. Blood cultures again grew Actinomyces pyogenes. TEE showed severe mitral valve regurgitation with numerous vegetations. Panorex showed multiple dental caries, but otherwise unremarkable. HIV was non-reactive. The patient denied licking his needles before injecting drugs or any animal contacts. Antibiotic management was guided by treatment of other Actinomyces infections. That included gentamicin and ampicillin, and was switched to IV penicillin G for a total duration of 12 weeks, followed by PO amoxicillin twice daily for 3 months. On outpatient follow-up, his focal deficits had improved, his aphasia resolved and he was ambulating. There are only two case reports of A. pyogenes infective endocarditis (IE) in the literature. One includes a patient with no reported animal exposure with multiple embolic complications who eventually succumbed to the infection. It is important for A. pyogenes to be considered in patients with IE, even with no history of typical exposures.https://scholarlycommons.henryford.com/merf2020caserpt/1090/thumbnail.jp

Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus

The combination of vancomycin or daptomycin plus ceftaroline has showed synergistic results in vitro. This study aimed to investigate in vitro synergy of vancomycin or daptomycin plus ceftaroline for seven patients with daptomycin non-susceptible Staphylococcus aureus (SA) bacteremia Thirteen isolates from seven patients were evaluated: two methicillin-susceptible and five methicillin-resistant SA infections. All patients were treated with daptomycin and became non-susceptible (minimum inhibitory concentration (MIC) \u3e1 μg/mL) with therapy or had resistant strains initially. Time kill experiments were completed with 0.25 × MIC, 0.5 × MIC, and 0.75 × MIC concentrations. No synergy was seen at 0.25 × MIC. Synergy was observed for 4 isolates with vancomycin plus ceftaroline and with daptomycin plus ceftaroline for 2 isolates at 0.5 × MIC. These results are in accordance with literature that supports synergistic combinations of daptomycin or vancomycin with ceftaroline for SA bacteremia. Daptomycin non-susceptible SA bacteremia presents a treatment challenge

Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study

BACKGROUND: Ceftriaxone-resistant (CRO-R) Escherichia coli bloodstream infections (BSIs) are common. METHODS: This is a prospective cohort of patients with E coli BSI at 14 United States hospitals between November 2020 and April 2021. For each patient with a CRO-R E coli BSI enrolled, the next consecutive patient with a ceftriaxone-susceptible (CRO-S) E coli BSI was included. Primary outcome was desirability of outcome ranking (DOOR) at day 30, with 50% probability of worse outcomes in the CRO-R group as the null hypothesis. Inverse probability weighting (IPW) was used to reduce confounding. RESULTS: Notable differences between patients infected with CRO-R and CRO-S E coli BSI included the proportion with Pitt bacteremia score ≥4 (23% vs 15%, P = .079) and the median time to active antibiotic therapy (12 hours [interquartile range {IQR}, 1-35 hours] vs 1 hour [IQR, 0-6 hours]; P \u3c .001). Unadjusted DOOR analyses indicated a 58% probability (95% confidence interval [CI], 52%-63%) for a worse clinical outcome in CRO-R versus CRO-S BSI. In the IPW-adjusted cohort, no difference was observed (54% [95% CI, 47%-61%]). Secondary outcomes included unadjusted and adjusted differences in the proportion of 30-day mortality between CRO-R and CRO-S BSIs (-5.3% [95% CI, -10.3% to -.4%] and -1.8 [95% CI, -6.7% to 3.2%], respectively), postculture median length of stay (8 days [IQR, 5-13 days] vs 6 days [IQR, 4-9 days]; P \u3c .001), and incident admission to a long-term care facility (22% vs 12%, P = .045). CONCLUSIONS: Patients with CRO-R E coli BSI generally have poorer outcomes compared to patients infected with CRO-S E coli BSI, even after adjusting for important confounders

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

BACKGROUND: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global threat, but the distribution and clinical significance of carbapenemases are unclear. The aim of this study was to define characteristics and outcomes of CRPA infections and the global frequency and clinical impact of carbapenemases harboured by CRPA. METHODS: We conducted an observational, prospective cohort study of CRPA isolated from bloodstream, respiratory, urine, or wound cultures of patients at 44 hospitals (10 countries) between Dec 1, 2018, and Nov 30, 2019. Clinical data were abstracted from health records and CRPA isolates were whole-genome sequenced. The primary outcome was 30-day mortality from the day the index culture was collected. We compared outcomes of patients with CRPA infections by infection type and across geographic regions and performed an inverse probability weighted analysis to assess the association between carbapenemase production and 30-day mortality. FINDINGS: We enrolled 972 patients (USA n=527, China n=171, south and central America n=127, Middle East n=91, Australia and Singapore n=56), of whom 581 (60%) had CRPA infections. 30-day mortality differed by infection type (bloodstream 21 [30%] of 69, respiratory 69 [19%] of 358, wound nine [14%] of 66, urine six [7%] of 88; p=0·0012) and geographical region (Middle East 15 [29%] of 52, south and central America 20 [27%] of 73, USA 60 [19%] of 308, Australia and Singapore three [11%] of 28, China seven [6%] of 120; p=0·0002). Prevalence of carbapenemase genes among CRPA isolates also varied by region (south and central America 88 [69%] of 127, Australia and Singapore 32 [57%] of 56, China 54 [32%] of 171, Middle East 27 [30%] of 91, USA ten [2%] of 527; p\u3c0·0001). KPC-2 (n=103 [49%]) and VIM-2 (n=75 [36%]) were the most common carbapenemases in 211 carbapenemase-producing isolates. After excluding USA patients, because few US isolates had carbapenemases, patients with carbapenemase-producing CRPA infections had higher 30-day mortality than those with non-carbapenemase-producing CRPA infections in both unadjusted (26 [22%] of 120 vs 19 [12%] of 153; difference 9%, 95% CI 3-16) and adjusted (difference 7%, 95% CI 1-14) analyses. INTERPRETATION: The emergence of different carbapenemases among CRPA isolates in different geographical regions and the increased mortality associated with carbapenemase-producing CRPA infections highlight the therapeutic challenges posed by these organisms. FUNDING: National Institutes of Health

Epidemiología mundial y resultados clínicos de Pseudomonas aeruginosa resistente a carbapenemes y carbapenemasas asociadas (POP): un estudio prospectivo de cohortes

Antecedentes: La Pseudomonas aeruginosa resistente a los carbapenemes (CRPA) es una amenaza mundial, pero la distribución y la importancia clínica de las carbapenemasas no están claras. El objetivo de este estudio fue definir las características y los resultados de las infecciones por CRPA, así como la frecuencia global y el impacto clínico de las carbapenemasas albergadas por CRPA. Métodos: Llevamos a cabo un estudio de cohortes observacional y prospectivo de CRPA aislados de cultivos de torrente sanguíneo, respiratorio, orina o heridas de pacientes en 44 hospitales (10 países) entre el 1 de diciembre de 2018 y el 30 de noviembre de 2019. Los datos clínicos se extrajeron de los registros de salud y los aislados de CRPA se secuenciaron en todo el genoma. El resultado primario fue la mortalidad a 30 días a partir del día en que se recolectó el cultivo índice. Se compararon los resultados de los pacientes con infecciones por CRPA por tipo de infección y entre regiones geográficas y se realizó un análisis ponderado de probabilidad inversa para evaluar la asociación entre la producción de carbapenemasas y la mortalidad a 30 días. Resultados: Se incluyeron 972 pacientes (EE.UU. n=527, China n=171, América del Sur y Central n=127, Oriente Medio n=91, Australia y Singapur n=56), de los cuales 581 (60%) tenían infecciones por CRPA. La mortalidad a los 30 días difería según el tipo de infección (torrente sanguíneo 21 [30%] de 69, respiratoria 69 [19%] de 358, herida nueve [14%] de 66, orina seis [7%] de 88; p=0-0012) y la región geográfica (Oriente Medio 15 [29%] de 52, América del Sur y Central 20 [27%] de 73, EE.UU. 60 [19%] de 308, Australia y Singapur tres [11%] de 28, China siete [6%] de 120; p=0-0002). La prevalencia de genes carbapenemasa entre los aislados CRPA también varió según la región (América del Sur y Central 88 [69%] de 127, Australia y Singapur 32 [57%] de 56, China 54 [32%] de 171, Oriente Medio 27 [30%] de 91, EE.UU. diez [2%] de 527; p<0-0001). KPC-2 (n=103 [49%]) y VIM-2 (n=75 [36%]) fueron las carbapenemasas más comunes en 211 aislados productores de carbapenemasas. Después de excluir a los pacientes de EE.UU., porque pocos aislados de EE.UU. tenían carbapenemasas, los pacientes con infecciones por CRPA productoras de carbapenemasas tuvieron una mayor mortalidad a los 30 días que aquellos con infecciones por CRPA no productoras de carbapenemasas, tanto en los análisis no ajustados (26 [22%] de 120 frente a 19 [12%] de 153; diferencia 9%, IC 95% 3-16) como ajustados (diferencia 7%, IC 95% 1-14). Interpretación: La aparición de diferentes carbapenemasas entre los aislados de CRPA en diferentes regiones geográficas y el aumento de la mortalidad asociada a las infecciones por CRPA productores de carbapenemasas ponen de manifiesto los retos terapéuticos que plantean estos organismos. Financiación: Institutos Nacionales de Salud.Background: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global threat, but the distribution and clinical significance of carbapenemases are unclear. The aim of this study was to define characteristics and outcomes of CRPA infections and the global frequency and clinical impact of carbapenemases harboured by CRPA. Methods: We conducted an observational, prospective cohort study of CRPA isolated from bloodstream, respiratory, urine, or wound cultures of patients at 44 hospitals (10 countries) between Dec 1, 2018, and Nov 30, 2019. Clinical data were abstracted from health records and CRPA isolates were whole-genome sequenced. The primary outcome was 30-day mortality from the day the index culture was collected. We compared outcomes of patients with CRPA infections by infection type and across geographic regions and performed an inverse probability weighted analysis to assess the association between carbapenemase production and 30-day mortality. Findings: We enrolled 972 patients (USA n=527, China n=171, south and central America n=127, Middle East n=91, Australia and Singapore n=56), of whom 581 (60%) had CRPA infections. 30-day mortality differed by infection type (bloodstream 21 [30%] of 69, respiratory 69 [19%] of 358, wound nine [14%] of 66, urine six [7%] of 88; p=0·0012) and geographical region (Middle East 15 [29%] of 52, south and central America 20 [27%] of 73, USA 60 [19%] of 308, Australia and Singapore three [11%] of 28, China seven [6%] of 120; p=0·0002). Prevalence of carbapenemase genes among CRPA isolates also varied by region (south and central America 88 [69%] of 127, Australia and Singapore 32 [57%] of 56, China 54 [32%] of 171, Middle East 27 [30%] of 91, USA ten [2%] of 527; p<0·0001). KPC-2 (n=103 [49%]) and VIM-2 (n=75 [36%]) were the most common carbapenemases in 211 carbapenemase-producing isolates. After excluding USA patients, because few US isolates had carbapenemases, patients with carbapenemase-producing CRPA infections had higher 30-day mortality than those with non-carbapenemase-producing CRPA infections in both unadjusted (26 [22%] of 120 vs 19 [12%] of 153; difference 9%, 95% CI 3–16) and adjusted (difference 7%, 95% CI 1–14) analyses. Interpretation: The emergence of different carbapenemases among CRPA isolates in different geographical regions and the increased mortality associated with carbapenemase-producing CRPA infections highlight the therapeutic challenges posed by these organisms. Funding: National Institutes of Health

Project #37: Management Guidelines for Patients with COVID-19: Rapid Cycle Improvement

Project’s purpose is to rapidly devise, continually improve, educate, and implement a live and changing COVID-19 management guideline based upon emerging best available evidence. This project also aims to optimize the care of patients with COVID-19 and improve patient outcomes.https://scholarlycommons.henryford.com/qualityexpo2022/1004/thumbnail.jp

Invasive aspergillosis of the liver in an immunocompetent patient

Introduction: Invasive aspergillosis is most often seen in immunocompromised patients, although there are rare case reports of infection in immunocompetent hosts. We present a case of an immunocompetent patient with isolated hepatic aspergillosis. Case presentation: A 77-year-old male with chronic kidney disease stage III and history of Whipple procedure for a benign pancreatic mass 12 years prior presented with 1.5 months of fatigue, decreased appetite, chills, nausea, vomiting and diarrhea. Prior to the onset of his illness he was active and functional. Exam was pertinent for right upper quadrant tenderness. Imaging at an outside institution revealed a large heterogeneous liver mass, which on biopsy showed granulomatous inflammation and fungal forms identified as aseptate hyphae concerning for mucormycosis. He was transferred to our hospital for surgical resection. A review of the pathology slides and repeat biopsy revealed fungal forms identified as acute angle branching septate hyphae most consistent with Aspergillus. Concurrent cultures grew Aspergillus fumigatus. Extensive work-up including imaging of the sinuses, lungs and abdomen, along with bronchoscopy, colonoscopy, and endoscopy were negative. He was started on amphotericin B and anidulafungin but amphotericin was changed to voriconazole when diagnosis of aspergillosis was confirmed. He was deemed high risk for surgery, given the extent of resection that would be required. Work up for malignancy was negative. His hospital course was complicated with worsening respiratory, liver and renal failure, and he expired on day 25. Discussion: Hepatic invasion by Aspergillus is uncommon, including in the immunocompromised. Our patient was immunocompetent but did have altered anatomy from his Whipple procedure and underwent regular instrumentation every few years with upper endoscopy. It is feasible that this allowed a portal of entry for Aspergillus to his GI tract. Another possibility is that he ingested food highly contaminated with Aspergillus which has been reported. Given the paucity of data for hepatic aspergillosis, optimal therapy remains unclear, and a rational approach is to combine medical and surgical therapy. Conclusion: This is a rare case of an immunocompetent patient with primary hepatic aspergillosis without another focus of infection. It highlights the diagnostic and management challenges faced with invasive gastrointestinal aspergillosis.https://scholarlycommons.henryford.com/merf2019caserpt/1035/thumbnail.jp

Can the One Health Approach Save Us from the Emergence and Reemergence of Infectious Pathogens in the Era of Climate Change: Implications for Antimicrobial Resistance?

Climate change has become a controversial topic in today’s media despite decades of warnings from climate scientists and has influenced human health significantly with the increasing prevalence of infectious pathogens and contribution to antimicrobial resistance. Elevated temperatures lead to rising sea and carbon dioxide levels, changing environments and interactions between humans and other species. These changes have led to the emergence and reemergence of infectious pathogens that have already developed significant antimicrobial resistance. Although these new infectious pathogens are alarming, we can still reduce the burden of infectious diseases in the era of climate change if we focus on One Health strategies. This approach aims at the simultaneous protection of humans, animals and environment from climate change and antimicrobial impacts. Once these relationships are better understood, these models can be created, but the support of our legislative and health system partnerships are critical to helping with strengthening education and awareness